vs
Side-by-side financial comparison of bioAffinity Technologies, Inc. (BIAF) and T Stamp Inc (IDAI). Click either name above to swap in a different company.
bioAffinity Technologies, Inc. is the larger business by last-quarter revenue ($1.6M vs $908.9K, roughly 1.8× T Stamp Inc). bioAffinity Technologies, Inc. runs the higher net margin — -197.0% vs -279.9%, a 82.9% gap on every dollar of revenue. On growth, bioAffinity Technologies, Inc. posted the faster year-over-year revenue change (-27.8% vs -39.3%). T Stamp Inc produced more free cash flow last quarter ($2.0M vs $-2.6M). Over the past eight quarters, T Stamp Inc's revenue compounded faster (25.9% CAGR vs -18.6%).
bioAffinity Technologies, Inc. is a clinical-stage biotechnology firm focused on developing non-invasive in vitro diagnostic tests for early detection of cancer and respiratory diseases. It serves global healthcare markets, with a core mission to deliver accessible, high-accuracy diagnostic solutions that improve patient outcomes and reduce overall healthcare system costs.
T Stamp Inc, trading under ticker IDAI, develops AI-powered identity verification, trust scoring, and fraud prevention solutions. It serves clients across fintech, healthcare, and e-commerce segments, primarily operating in North America to help organizations securely authenticate user identities and mitigate fraud risks.
BIAF vs IDAI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.6M | $908.9K |
| Net Profit | $-3.1M | $-2.5M |
| Gross Margin | — | — |
| Operating Margin | -196.9% | -224.9% |
| Net Margin | -197.0% | -279.9% |
| Revenue YoY | -27.8% | -39.3% |
| Net Profit YoY | -5.7% | 57.7% |
| EPS (diluted) | $-3.59 | $-0.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.6M | $908.9K | ||
| Q3 25 | $1.4M | $872.5K | ||
| Q2 25 | $1.3M | $812.7K | ||
| Q1 25 | $1.9M | $545.5K | ||
| Q4 24 | $2.2M | $1.5M | ||
| Q3 24 | $2.4M | $511.1K | ||
| Q2 24 | $2.4M | $500.4K | ||
| Q1 24 | $2.4M | $573.7K |
| Q4 25 | $-3.1M | $-2.5M | ||
| Q3 25 | $-5.1M | $-1.9M | ||
| Q2 25 | $-4.1M | $-1.7M | ||
| Q1 25 | $-2.7M | $-2.2M | ||
| Q4 24 | $-3.0M | $-6.0M | ||
| Q3 24 | $-2.0M | $-1.3M | ||
| Q2 24 | $-2.1M | $-2.6M | ||
| Q1 24 | $-2.0M | $-2.7M |
| Q4 25 | -196.9% | -224.9% | ||
| Q3 25 | -158.6% | -203.0% | ||
| Q2 25 | -198.2% | -207.0% | ||
| Q1 25 | -141.7% | -396.5% | ||
| Q4 24 | -133.5% | -81.2% | ||
| Q3 24 | -84.0% | -523.7% | ||
| Q2 24 | -87.1% | -524.7% | ||
| Q1 24 | -80.8% | -496.7% |
| Q4 25 | -197.0% | -279.9% | ||
| Q3 25 | -349.3% | -219.1% | ||
| Q2 25 | -319.9% | -210.7% | ||
| Q1 25 | -143.5% | -395.5% | ||
| Q4 24 | -134.4% | -401.5% | ||
| Q3 24 | -85.1% | -245.7% | ||
| Q2 24 | -88.0% | -519.3% | ||
| Q1 24 | -81.5% | -466.9% |
| Q4 25 | $-3.59 | $-0.37 | ||
| Q3 25 | $-4.74 | $-0.72 | ||
| Q2 25 | $-0.17 | $-0.69 | ||
| Q1 25 | $-0.16 | $-0.89 | ||
| Q4 24 | $-17.27 | $-3.14 | ||
| Q3 24 | $-4.84 | $-1.06 | ||
| Q2 24 | $-0.19 | $-3.19 | ||
| Q1 24 | $-0.20 | $-3.97 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $6.4M | $6.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $7.3M | $8.7M |
| Total Assets | $11.0M | $11.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $6.4M | $6.0M | ||
| Q3 25 | $7.7M | $5.4M | ||
| Q2 25 | $802.8K | $292.1K | ||
| Q1 25 | $444.7K | $1.1M | ||
| Q4 24 | $1.1M | $2.8M | ||
| Q3 24 | $756.6K | $598.0K | ||
| Q2 24 | $801.3K | $659.5K | ||
| Q1 24 | $2.5M | $816.7K |
| Q4 25 | $7.3M | $8.7M | ||
| Q3 25 | $8.9M | $6.1M | ||
| Q2 25 | $-2.1M | $2.4M | ||
| Q1 25 | $1.4M | $4.1M | ||
| Q4 24 | $2.6M | $3.0M | ||
| Q3 24 | $3.1M | $5.4M | ||
| Q2 24 | $3.4M | $750.4K | ||
| Q1 24 | $5.3M | $1.4M |
| Q4 25 | $11.0M | $11.2M | ||
| Q3 25 | $11.5M | $11.2M | ||
| Q2 25 | $4.8M | $5.7M | ||
| Q1 25 | $5.5M | $6.6M | ||
| Q4 24 | $6.5M | $8.6M | ||
| Q3 24 | $6.6M | $10.6M | ||
| Q2 24 | $6.7M | $5.2M | ||
| Q1 24 | $8.0M | $5.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.6M | $2.0M |
| Free Cash FlowOCF − Capex | $-2.6M | $2.0M |
| FCF MarginFCF / Revenue | -160.7% | 215.4% |
| Capex IntensityCapex / Revenue | 0.0% | 0.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-9.4M | $-5.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.6M | $2.0M | ||
| Q3 25 | $-2.5M | $-4.0M | ||
| Q2 25 | $-2.6M | $-2.1M | ||
| Q1 25 | $-1.6M | $-1.5M | ||
| Q4 24 | $-1.7M | $-2.7M | ||
| Q3 24 | $-1.7M | $-2.4M | ||
| Q2 24 | $-1.5M | $-1.6M | ||
| Q1 24 | $-2.3M | $-2.2M |
| Q4 25 | $-2.6M | $2.0M | ||
| Q3 25 | $-2.5M | $-4.0M | ||
| Q2 25 | $-2.7M | $-2.1M | ||
| Q1 25 | $-1.7M | $-1.6M | ||
| Q4 24 | $-1.7M | $-2.7M | ||
| Q3 24 | $-1.7M | $-2.4M | ||
| Q2 24 | $-1.6M | $-1.6M | ||
| Q1 24 | $-2.4M | $-2.2M |
| Q4 25 | -160.7% | 215.4% | ||
| Q3 25 | -171.8% | -459.6% | ||
| Q2 25 | -209.6% | -258.6% | ||
| Q1 25 | -91.3% | -289.2% | ||
| Q4 24 | -76.0% | -182.9% | ||
| Q3 24 | -73.1% | -475.4% | ||
| Q2 24 | -65.1% | -320.9% | ||
| Q1 24 | -99.2% | -376.6% |
| Q4 25 | 0.0% | 0.8% | ||
| Q3 25 | 0.3% | 0.0% | ||
| Q2 25 | 1.1% | 0.2% | ||
| Q1 25 | 2.7% | 6.8% | ||
| Q4 24 | 0.0% | 0.1% | ||
| Q3 24 | 0.4% | 0.7% | ||
| Q2 24 | 1.2% | 1.3% | ||
| Q1 24 | 1.7% | 0.5% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
